1. Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int 2007;100:987-1006. PMID:
17922784
2. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5-26. PMID:
15885877
4. Harding MCL, Arlandis S, Bø K, Costantini E, Groen J, Nambiar AK, et al. EAU Guidelines on Non-neurogenic Female LUTS. In: 36th EAU Annual Congress; 2021.
5. Arrighi N, Bodei S, Peroni A, Mirabella G, Zani D, Simeone C, et al. Detection of muscarinic receptor subtypes in human urinary bladder mucosa: age and gender-dependent modifications. Neurourol Urodyn 2008;27:421-8. PMID:
17924537
7. Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420-9 discussion 9. PMID:
15041104
8. Andersson KE. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004;3:46-53. PMID:
14693111
9. Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002;60:82-8 discussion 8-9. PMID:
12493364
10. Chapple CR, Nazir J, Hakimi Z, Bowditch S, Fatoye F, Guelfucci F, et al. Persistence and adherence with mirabegron versus antimuscarinic agents in patients with overactive bladder: a retrospective observational study in UK clinical practice. Eur Urol 2017;72:389-99. PMID:
28196724
11. Lee MJ, Moon JH, Lee HK, Cho CH, Choi SH, Im WB. Pharmacological characterization of DA-8010, a novel muscarinic receptor antagonist selective for urinary bladder over salivary gland. Eur J Pharmacol 2019;843:240-50. PMID:
30502343
12. Lee MJ, Moon JH, Lee HK, Shin YM, Park HS, Kim YN, et al. In vivo selectivity of DA-8010 for the bladder over the brain: effects on bladder intravesical pressure, brain muscarinic receptor occupancy, and cognitive function in mice [abstract]. J Urol 2019;201(Suppl 4):e231.
14. Mostafaei H, Janisch F, Mori K, Quhal F, Pradere B, Hajebrahimi S, et al. Placebo response in patients with oral therapy for overactive bladder: a systematic review and meta-analysis. Eur Urol Focus 2022;8:239-52. PMID:
33674256
15. Chapple C, Steers W, Norton P, Millard R, Kralidis G, Glavind K, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005;95:993-1001. PMID:
15839920
17. Chapple CR, Araño P, Bosch JL, De Ridder D, Kramer AE, Ridder AM. Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 2004;93:71-7. PMID:
14678372